Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - suhi ekstrakt bršljanovog lista (4-8 : 1), ekstrakcijsko otapalo: etanol 30 % (m/m) - sirup - 3,675 mg/ml - urbroj: 1 mililitar sirupa sadrži 3,675 mg ekstrakta (kao suhi ekstrakt) iz hedera helix l., folium (bršljanov list) (4–8 : 1); ekstrakcijsko otapalo: etanol 30% m/m

Den europeiske union - kroatisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - hrskavičav inducirana periferne krvi konja аллогенных мезенхимальных matičnih stanica - ostali lijekovi za poremećaje mišićno-koštanog sustava - konji - smanjenje od blage do umjerene relaps хромотой povezane s септическим upalom zglobova u konja.

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - benzidaminklorid - otopina za grgljanje/ispiranje usta - 1,5 mg/ml - urbroj: 1 ml otopine sadrži 1,5 mg benzidaminklorida (što odgovara 1,34 mg benzidamina)

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

mediva d.o.o. savska cesta 141 10000 zagreb -

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

mediva d.o.o. savska cesta 141 10000 zagreb -

Den europeiske union - kroatisk - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - zolgensma indiciran za liječenje bolesnika s 5v spinalne mišićne atrofije (agr) sa bi-аллельные mutacije u genu smn1 i kliničku dijagnozu agr tip 1, orpatients sa 5v agr s bi-аллельные mutacije u genu smn1 i do 3-x kopija gena smn2.

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

sol s.p.a., via borgazzi 27, monza, italija - dušikov (i) oksid kisik - medicinski plin, stlačen - 50%/50% v/v - urbroj: svaki spremnik sadrži 50% v/v dušičnog oksidula i 50% v/v kisika pod tlakom od 135 ili 185 bara (15°c)

Den europeiske union - kroatisk - EMA (European Medicines Agency)

intervet international b.v. - cellular " potpomognuta živa рекомбинантная turske герпесвирус (soj hvp360), izražavajući sintezu proteina virusa nd i vp2 s proteinima virusa ИБД - ptica virus herpesa (bolest Марека) + ptičji virus infektivne бурсальной bolesti (bolest Гамборо) + virusa ньюкаслской bolesti/парамиксовируса - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - imunološki za aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunološki za aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).